Soleno Therapeutics, Inc. (SLNO) is a Biotechnology company in the Healthcare sector, currently trading at $52.62. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of SLNO = $211.36 (+301.7% from the current price, the stock appears undervalued). Analyst consensus target is SLNO = $95 (+81% upside).
Valuation: SLNO trades at a trailing Price-to-Earnings (P/E) of 133.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.26.
Financials: revenue is $190M, +0%/yr average growth. Net income is $21M, growing at -110.3%/yr. Net profit margin is 11% (healthy). Gross margin is 98.6% (+0 pp trend).
Balance sheet: total debt is $3M against $450M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 5.8 (strong liquidity). Debt-to-assets is 0.5%. Total assets: $564M.
Analyst outlook: 9 / 13 analysts rate SLNO as buy (69%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 53/100 (Partial), Growth 15/100 (Fail), Past 25/100 (Fail), Health 67/100 (Partial), Moat 66/100 (Partial), Future 73/100 (Pass), Income 55/100 (Partial).
